Research programme: cannabidiol conjugated skin disorder therapeutics - Diverse Biotech/Enveric Biosciences

Alternative Names: CBD-conjugated skin disorder therapeutics - Diverse Biotech/Enveric Biosciences

Latest Information Update: 08 Apr 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Diverse Biotech
Developer Enveric Biosciences
Class Anti-inflammatories; Cannabinoids; Cyclohexenes; Drug conjugates; Skin disorder therapies; Small molecules
Mechanism of Action 5-HT1 serotonin receptor modulators; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

10 Mar 2021 Cannabinoid conjugated skin disorder therapeutics licensed to Enveric Biosciences worldwide for the treatment of Skin disorders associated with cancer
10 Mar 2021 Early research in Skin disorders in Italy (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com